Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2010

Open Access 01-12-2010 | Research

Role of the atypical chemoattractant receptor CRAM in regulating CCL19 induced CCR7 responses in B-cell chronic lymphocytic leukemia

Authors: Julie Catusse, Marion Leick, Mareike Groch, David J Clark, Maike V Buchner, Katja Zirlik, Meike Burger

Published in: Molecular Cancer | Issue 1/2010

Login to get access

Abstract

Background

The non-signalling chemokine receptors, including receptors DARC, D6 and CCX-CKR, have recently been shown to be involved in chemokine clearance and activity regulation. The human chemokine receptor CRAM (also known as HCR or CCRL2) is the most recently identified member of this atypical group. CRAM is expressed on B cells in a maturation-stage dependent manner and absent on T cells. We have recently shown that it competitively binds CCL19. CCL19 and its signalling receptor CCR7 are critical components involved in cell recruitment to secondary lymphoid organs and in maturation. B cell Chronic Lymphocytic Leukemia (B-CLL) is a low-grade lymphoma characterized by proliferative centres (or pseudofollicles). Proliferative centres develop due to abnormal cellular localisation and they are involved in the development of malignant cells. CCR7 is highly expressed on B cells from CLL patients and mediates migration towards its ligands CCL19 and CCL21, while CRAM expression and potential interferences with CCR7 are yet to be characterized.

Results

In this study, we show that B cells from patients with B-CLL present highly variable degrees of CRAM expression in contrast to more consistently high levels of CCR7. We investigated the hypothesis that, similar to the atypical receptor DARC, CRAM can modulate chemokine availability and/or efficacy, resulting in the regulation of cellular activation. We found that a high level of CRAM expression was detrimental to efficient chemotaxis with CCL19. MAP-kinase phosphorylation and intracellular calcium release induced by CCL19 were also altered by CRAM expression. In addition, we demonstrate that CRAM-induced regulation of CCL19 signalling is maintained over time.

Conclusions

We postulate that CRAM is a factor involved in the fine tuning/control of CCR7/CCL19 mediated responses. This regulation could be critical to the pivotal role of CCL19 induced formation of proliferation centres supporting the T/B cells encounter as well as disease progression in B-CLL.
Appendix
Available only for authorised users
Literature
1.
Caligaris-Cappio F, Ghia P: Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease?. J Clin Oncol. 2008, 26: 4497-4503. 10.1200/JCO.2007.15.4393CrossRefPubMed
2.
Rot A, von Andrian UH: Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol. 2004, 22: 891-928. 10.1146/annurev.immunol.22.012703.104543CrossRefPubMed
3.
Ticchioni M, Essafi M, Jeandel PY, Davi F, Cassuto JP, Deckert M, Bernard A: Homeostatic chemokines increase survival of B-chronic lymphocytic leukemia cells through inactivation of transcription factor FOXO3a. Oncogene. 2007, 26: 7081-7091. 10.1038/sj.onc.1210519CrossRefPubMed
4.
Yoshida R, Nagira M, Kitaura M, Imagawa N, Imai T, Yoshie O: Secondary lymphoid-tissue chemokine is a functional ligand for the CC chemokine receptor CCR7. J Biol Chem. 1998, 273: 7118-7122. 10.1074/jbc.273.12.7118CrossRefPubMed
5.
Christopherson KW, Campbell JJ, Travers JB, Hromas RA: Low-molecular-weight heparins inhibit CCL21-induced T cell adhesion and migration. J Pharmacol Exp Ther. 2002, 302: 290-295. 10.1124/jpet.302.1.290CrossRefPubMed
6.
de Paz JL, Moseman EA, Noti C, Polito L, von Andrian UH, Seeberger PH: Profiling heparin-chemokine interactions using synthetic tools. ACS Chem Biol. 2007, 2: 735-744. 10.1021/cb700159mPubMedCentralCrossRefPubMed
7.
Bardi G, Lipp M, Baggiolini M, Loetscher P: The T cell chemokine receptor CCR7 is internalized on stimulation with ELC, but not with SLC. Eur J Immunol. 2001, 31: 3291-3297. 10.1002/1521-4141(200111)31:11<3291::AID-IMMU3291>3.0.CO;2-ZCrossRefPubMed
8.
Kohout TA, Nicholas SL, Perry SJ, Reinhart G, Junger S, Struthers RS: Differential desensitization, receptor phosphorylation, beta-arrestin recruitment, and ERK1/2 activation by the two endogenous ligands for the CC chemokine receptor 7. J Biol Chem. 2004, 279: 23214-23222. 10.1074/jbc.M402125200CrossRefPubMed
9.
Baekkevold ES, Yamanaka T, Palframan RT, Carlsen HS, Reinholt FP, von Andrian UH, Brandtzaeg P, Haraldsen G: The CCR7 ligand elc (CCL19) is transcytosed in high endothelial venules and mediates T cell recruitment. J Exp Med. 2001, 193: 1105-1112. 10.1084/jem.193.9.1105PubMedCentralCrossRefPubMed
10.
Comerford I, Milasta S, Morrow V, Milligan G, Nibbs R: The chemokine receptor CCX-CKR mediates effective scavenging of CCL19 in vitro. Eur J Immunol. 2006, 36: 1904-1916. 10.1002/eji.200535716CrossRefPubMed
11.
Gosling J, Dairaghi DJ, Wang Y, Hanley M, Talbot D, Miao Z, Schall TJ: Cutting edge: identification of a novel chemokine receptor that binds dendritic cell- and T cell-active chemokines including ELC, SLC, and TECK. J Immunol. 2000, 164: 2851-2856.CrossRefPubMed
12.
Weber M, Blair E, Simpson CV, O'Hara M, Blackburn PE, Rot A, Graham GJ, Nibbs RJ: The chemokine receptor D6 constitutively traffics to and from the cell surface to internalize and degrade chemokines. Mol Biol Cell. 2004, 15: 2492-2508. 10.1091/mbc.E03-09-0634PubMedCentralCrossRefPubMed
13.
Fra AM, Locati M, Otero K, Sironi M, Signorelli P, Massardi ML, Gobbi M, Vecchi A, Sozzani S, Mantovani A: Cutting edge: scavenging of inflammatory CC chemokines by the promiscuous putatively silent chemokine receptor D6. J Immunol. 2003, 170: 2279-2282.CrossRefPubMed
14.
Pruenster M, Mudde L, Bombosi P, Dimitrova S, Zsak M, Middleton J, Richmond A, Graham GJ, Segerer S, Nibbs RJ, Rot A: The Duffy antigen receptor for chemokines transports chemokines and supports their promigratory activity. Nat Immunol. 2009, 10: 101-108. 10.1038/ni.1675PubMedCentralCrossRefPubMed
15.
Hartmann TN, Leick M, Ewers S, Diefenbacher A, Schraufstatter I, Honczarenko M, Burger M: Human B cells express the orphan chemokine receptor CRAM-A/B in a maturation-stage-dependent and CCL5-modulated manner. Immunology. 2008, 125: 252-262. 10.1111/j.1365-2567.2008.02836.xPubMedCentralCrossRefPubMed
16.
Leick M, Catusse J, Follo M, Nibbs RJ, Hartmann TN, Veelken H, Burger M: CCL19 is a specific ligand of the constitutively recycling atypical human chemokine receptor CRAM-B. Immunology. 2010, 129: 536-546. 10.1111/j.1365-2567.2009.03209.xPubMedCentralCrossRefPubMed
17.
Zabel BA, Nakae S, Zuniga L, Kim JY, Ohyama T, Alt C, Pan J, Suto H, Soler D, Allen SJ, Handel TM, Song CH, Galli SJ, Butcher EC: Mast cell-expressed orphan receptor CCRL2 binds chemerin and is required for optimal induction of IgE-mediated passive cutaneous anaphylaxis. J Exp Med. 2008, 205: 2207-2220. 10.1084/jem.20080300PubMedCentralCrossRefPubMed
18.
Corcione A, Arduino N, Ferretti E, Raffaghello L, Roncella S, Rossi D, Fedeli F, Ottonello L, Trentin L, Dallegri F, Semenzato G, Pistoia V: CCL19 and CXCL12 trigger in vitro chemotaxis of human mantle cell lymphoma B cells. Clin Cancer Res. 2004, 10: 964-971. 10.1158/1078-0432.CCR-1182-3CrossRefPubMed
19.
Badr G, Borhis G, Treton D, Richard Y: IFN{alpha} enhances human B-cell chemotaxis by modulating ligand-induced chemokine receptor signaling and internalization. Int Immunol. 2005, 17: 459-467. 10.1093/intimm/dxh227CrossRefPubMed
20.
Honczarenko M, Glodek AM, Swierkowski M, Na IK, Silberstein LE: Developmental stage-specific shift in responsiveness to chemokines during human B-cell development. Exp Hematol. 2006, 34: 1093-1100. 10.1016/j.exphem.2006.05.013CrossRefPubMed
21.
Otero C, Groettrup M, Legler DF: Opposite fate of endocytosed CCR7 and its ligands: recycling versus degradation. J Immunol. 2006, 177: 2314-2323.CrossRefPubMed
22.
Byers MA, Calloway PA, Shannon L, Cunningham HD, Smith S, Li F, Fassold BC, Vines CM: Arrestin 3 mediates endocytosis of CCR7 following ligation of CCL19 but not CCL21. J Immunol. 2008, 181: 4723-4732.CrossRefPubMed
23.
Luttrell LM, Lefkowitz RJ: The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci. 2002, 115: 455-465.PubMed
24.
Neel NF, Schutyser E, Sai J, Fan GH, Richmond A: Chemokine receptor internalization and intracellular trafficking. Cytokine Growth Factor Rev. 2005, 16: 637-658. 10.1016/j.cytogfr.2005.05.008PubMedCentralCrossRefPubMed
25.
Fukuma N, Akimitsu N, Hamamoto H, Kusuhara H, Sugiyama Y, Sekimizu K: A role of the Duffy antigen for the maintenance of plasma chemokine concentrations. Biochem Biophys Res Commun. 2003, 303: 137-139. 10.1016/S0006-291X(03)00293-6CrossRefPubMed
26.
Townson JR, Nibbs RJ: Characterization of mouse CCX-CKR, a receptor for the lymphocyte-attracting chemokines TECK/mCCL25, SLC/mCCL21 and MIP-3beta/mCCL19: comparison to human CCX-CKR. Eur J Immunol. 2002, 32: 1230-1241. 10.1002/1521-4141(200205)32:5<1230::AID-IMMU1230>3.0.CO;2-LCrossRefPubMed
27.
Stillie R, Farooq SM, Gordon JR, Stadnyk AW: The functional significance behind expressing two IL-8 receptor types on PMN. J Leukoc Biol. 2009, 86: 529-543. 10.1189/jlb.0208125CrossRefPubMed
28.
Heinzel K, Benz C, Bleul CC: A silent chemokine receptor regulates steady-state leukocyte homing in vivo. Proc Natl Acad Sci USA. 2007, 104: 8421-8426. 10.1073/pnas.0608274104PubMedCentralCrossRefPubMed
29.
Galligan CL, Matsuyama W, Matsukawa A, Mizuta H, Hodge DR, Howard OM, Yoshimura T: Up-regulated expression and activation of the orphan chemokine receptor, CCRL2, in rheumatoid arthritis. Arthritis Rheum. 2004, 50: 1806-1814. 10.1002/art.20275CrossRefPubMed
30.
Auer J, Blass M, Schulze-Koops H, Russwurm S, Nagel T, Kalden JR, Rollinghoff M, Beuscher HU: Expression and regulation of CCL18 in synovial fluid neutrophils of patients with rheumatoid arthritis. Arthritis Res Ther. 2007, 9: R94- 10.1186/ar2294PubMedCentralCrossRefPubMed
31.
Burman A, Haworth O, Hardie DL, Amft EN, Siewert C, Jackson DG, Salmon M, Buckley CD: A chemokine-dependent stromal induction mechanism for aberrant lymphocyte accumulation and compromised lymphatic return in rheumatoid arthritis. J Immunol. 2005, 174: 1693-1700.PubMedCentralCrossRefPubMed
32.
Ghobrial IM, McCormick DJ, Kaufmann SH, Leontovich AA, Loegering DA, Dai NT, Krajnik KL, Stenson MJ, Melhem MF, Novak AJ, Ansell SM, Witzig TE: Proteomic analysis of mantle-cell lymphoma by protein microarray. Blood. 2005, 105: 3722-3730. 10.1182/blood-2004-10-3999PubMedCentralCrossRefPubMed
33.
Till KJ, Lin K, Zuzel M, Cawley JC: The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. Blood. 2002, 99: 2977-2984. 10.1182/blood.V99.8.2977CrossRefPubMed
34.
Alfonso-Perez M, Lopez-Giral S, Quintana NE, Loscertales J, Martin-Jimenez P, Munoz C: Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia. J Leukoc Biol. 2006, 79: 1157-1165. 10.1189/jlb.1105623CrossRefPubMed
35.
Jahnke K, Thiel E, Schilling A, Herrlinger U, Weller M, Coupland SE, Krumpelmann U, Stein H, Korfel A: Low-grade primary central nervous system lymphoma in immunocompetent patients. Br J Haematol. 2005, 128: 616-624. 10.1111/j.1365-2141.2004.05361.xCrossRefPubMed
36.
Chunsong H, Yuling H, Li W, Jie X, Gang Z, Qiuping Z, Qingping G, Kejian Z, Li Q, Chang AE, Youxin J, Jinquan T: CXC chemokine ligand 13 and CC chemokine ligand 19 cooperatively render resistance to apoptosis in B cell lineage acute and chronic lymphocytic leukemia CD23+CD5+ B cells. J Immunol. 2006, 177: 6713-6722.CrossRefPubMed
37.
Martinez-Delgado B, Melendez B, Cuadros M, Alvarez J, Castrillo JM, Ruiz De La Parte A, Mollejo M, Bellas C, Diaz R, Lombardia L, Al-Shahrour F, Dominguez O, Cascon A, Robledo M, Rivas C, Benitez J: Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes. Clin Cancer Res. 2004, 10: 4971-4982. 10.1158/1078-0432.CCR-04-0269CrossRefPubMed
38.
Bromley SK, Thomas SY, Luster AD: Chemokine receptor CCR7 guides T cell exit from peripheral tissues and entry into afferent lymphatics. Nat Immunol. 2005, 6: 895-901. 10.1038/ni1240CrossRefPubMed
Metadata
Title
Role of the atypical chemoattractant receptor CRAM in regulating CCL19 induced CCR7 responses in B-cell chronic lymphocytic leukemia
Authors
Julie Catusse
Marion Leick
Mareike Groch
David J Clark
Maike V Buchner
Katja Zirlik
Meike Burger
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2010
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-9-297

Other articles of this Issue 1/2010

Molecular Cancer 1/2010 Go to the issue

Research

Molecular assays for the detection of prostate tumor derived nucleic acids in peripheral blood

Short communication

Identification of non-coding RNAs embracing microRNA-143/145 cluster

Research

RHOA and PRKCZ control different aspects of cell motility in pancreatic cancer metastatic clones

Research

Inositol 1,4,5-trisphosphate-induced Ca2+ signalling is involved in estradiol-induced breast cancer epithelial cell growth

Research

The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine

Research

Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1α and HIF-2α target genes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits